Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commercial

Strategy Explore this Topic

Set Alert for Strategy

Celltrion Selected For Korean-Made Insulin Biosimilar

Korean firm Celltrion is aiming to move production of insulin pens inside Korea “for the first time” and break the stranglehold of Big Pharma insulin players in the market by launching a biosimilar product in 2025.

Biosimilars Strategy

Mylan And Lupin Prepare To Launch EU Etanercept

Mylan and Lupin have revealed when they expect to launch their etanercept biosimilar, Nepexto, in Europe after receiving formal European Commission approval.

Biosimilars Approvals

Alvogen Group Unveils Adalvo B2B Unit

The Alvogen group of companies has unveiled Adalvo as the new identity for its B2B business unit. In an exclusive interview, general manager Anil Okay talks to Generics Bulletin about the reasons behind the rebranding, what makes it unique in the B2B sphere, and the significance of 2023 for Adalvo’s strategy.

Strategy Manufacturing
See All

Deals Explore this Topic

Set Alert for Deals

Mylan And Pfizer Announce Key Date For Viatris Merger

Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.

Deals Strategy

Zentiva Opens India Office As It Completes Ankleshwar Plant Deal

Zentiva is opening a dedicated Indian office in Mumbai to support the Ankleshwar manufacturing facility that it has just acquired from former parent company Sanofi.

Strategy Manufacturing

Amgen Chooses To Settle In US Soliris IPR Tussle

Amgen’s burgeoning biosimilar presence continues to grow apace and now the company has eyes firmly on the US market for eculizumab after brokering a deal with originator Alexion. The biosimilars developer chose to settle on three of Alexion’s patents ahead of a trial later this year.

Deals Biosimilars
See All

Manufacturing Explore this Topic

Set Alert for Manufacturing

AAM Urges US Senate To Back Domestic Production

While the AAM is lobbying for a renewed focus on domestic drug production amid fresh concerns about the globalization of the US pharmaceutical drug supply chain, the association has urged US Congress to have confidence in FDA oversight, insisting that “the US has one of the safest drug supply chains in the world.”

Manufacturing United States

Alvogen Group Unveils Adalvo B2B Unit

The Alvogen group of companies has unveiled Adalvo as the new identity for its B2B business unit. In an exclusive interview, general manager Anil Okay talks to Generics Bulletin about the reasons behind the rebranding, what makes it unique in the B2B sphere, and the significance of 2023 for Adalvo’s strategy.

Strategy Manufacturing

Zentiva Opens India Office As It Completes Ankleshwar Plant Deal

Zentiva is opening a dedicated Indian office in Mumbai to support the Ankleshwar manufacturing facility that it has just acquired from former parent company Sanofi.

Strategy Manufacturing
See All

Sales & Earnings Explore this Topic

Set Alert for Sales & Earnings

COVID-19 Demand Gives Lupin Optimism On Albuterol

Lupin hopes a surge in demand for albuterol sulphate due to increased off-label use in COVID-19 patients will help its generic version, which is likely to be launched in the first half of FY21. But the Indian firm may recall a batch of metformin after the US FDA recently asked a few companies to retract extended-release versions due to NDMA concerns.

Strategy Coronavirus COVID-19

Sun Sees New Prescriptions Drought Amid COVID-19

Sun Pharma says that the first quarter of financial 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.

Strategy Coronavirus COVID-19

Torrent Outlook Muted On COVID-19

After a tepid performance in the fiscal fourth quarter, Torrent expects its key markets India, US and Brazil to be impacted by the COVID-19 fallout as well as a lack of visibility on regulatory approvals for its manufacturing facilities.

Strategy Sales & Earnings
See All

People Explore this Topic

Set Alert for People

Alvotech Gears Up For Public Listing With Fresh Leadership

Alvotech has brought in public markets specialist Tanya Zharov as deputy CEO for the firm in Iceland, as it prepares for a public listing.

Strategy Appointments

Who’s Hired? Stenico Takes Lead At Sandoz Germany

Sandoz has named Peter Stenico as permanent country head for its German operations. At the same time, Stada has appointed a trio of executives to key roles in Germany, Hovione has announced a new COO, Hikma and Orion have seen board changes and Sanofi’s biosimilars head in China has left the position for a new role.

Appointments Germany

ANI Names Interim CEO As Przybyl Prepares To Step Down

ANI revealed last month that long-serving company head Arthur Przybyl would be departing after 11 years at the top. The US-based player has just announced its interim chief as it reported first-quarter sales, following the landmark US portfolio acquisition from Amerigen in January, and made a major announcement for its full-year financial guidance.

Appointments Strategy
See All
UsernamePublicRestriction

Register